Biotechnology Value Fund is a San Francisco-based private investment partnership specializing in fundamentally-driven public biotechnology investments.
689彩票邀请码Since its inception in 1993, BVF has strived to build concentrated, long-term investments in small-cap biotechnology companies while performing rigorous diligence and on-going monitoring of its investments.
BVF is committed to working with its portfolio companies as partners in their successes.
Series C - Kymera Therapeutics
Post-IPO Debt - Syndax Pharmaceuticals
Series C - Revolution Medicines
Venture Round - Phathom Pharmaceuticals
Series B - Vividion Therapeutics
Series B - Prevail Therapeutics
Series E - Peloton Therapeutics
Series C - Relay Therapeutics
Series B - Akero Therapeutics
Series A - Rain Therapeutics
Number of Organizations
Early Stage Venture Investors with Investments in Western US
Venture Capital Investors with Investments in Utrecht, Utrecht
San Francisco Investors
Early Stage Venture Investors with Investments in Silicon Valley
Investors Active in Palo Alto, California
Investors Active in Switzerland
Early Stage Venture Investors with Investments in Northeastern US
California Venture Capital Investors
Early Stage Venture Investors Venture Capital Investors
Investors Active in Greater Seattle Area